Allakos INC 8-K filings

Allakos Inc. finalizes its merger with Concentra Biosciences, resulting in the company becoming a wholly-owned subsidiary and delisting from the Nasdaq Global Select Market.

Allakos Inc. has entered into a definitive agreement to be acquired by Concentra Biosciences, LLC for $0.33 per share in cash.

Allakos Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Allakos reports Q4 2024 financial results, provides a business update including discontinuing AK006 development, restructuring operations, and exploring strategic alternatives.

Allakos Inc. will discontinue development of AK006, reduce its workforce by 75%, and explore strategic alternatives after a Phase 1 study in Chronic Spontaneous Urticaria (CSU).

Allakos Inc. announced the discontinuation of its AK006 program after disappointing clinical trial results, leading to a significant workforce reduction and exploration of strategic alternatives.

Allakos Inc. has agreed to terminate its headquarters lease, incurring approximately $4 million in costs, including a $2.3 million lease modification payment and $1.7 million in broker commissions.

Allakos announced positive results from its Phase 1 trial of subcutaneous AK006, along with its third quarter 2024 financial results, highlighting a decrease in operating expenses and a net loss of $18.4 million.

Allakos Inc. released an updated corporate presentation highlighting the progress of its AK006 clinical program and providing a financial update.

Allakos reports successful Phase 1 trial results for subcutaneous AK006 in healthy volunteers, demonstrating high bioavailability and prolonged receptor occupancy on mast cells.

Allakos Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing status at risk.

Allakos Inc. announced its second quarter 2024 financial results, highlighting a decrease in operating expenses and a net loss of $26.7 million, while also providing updates on its clinical trial progress for AK006.

Allakos Inc. released an updated corporate presentation detailing the progress of its AK006 clinical program and providing a financial update, including an estimated cash runway into mid-2026.

Allakos reports positive results from its Phase 1 trial of AK006, demonstrating high receptor occupancy on mast cells and a favorable safety profile in healthy volunteers.

Allakos Inc. held its 2024 Annual Meeting of Stockholders, where directors were elected, the independent auditor was ratified, and executive compensation was approved on an advisory basis.

Allakos has initiated a Phase 1 clinical trial for AK006 in chronic spontaneous urticaria, with top-line results expected by the end of 2024.

Allakos Inc. announced its first quarter 2024 financial results, highlighting progress in its AK006 clinical trials and reiterating its cash runway guidance.

Allakos Inc. has announced changes to its Board of Directors, including the reclassification of a director and the departure of two others, to more evenly distribute board membership.

Allakos halts lirentelimab development, restructures to focus on AK006, and anticipates cash runway extension into mid-2026.

Allakos announced a poster presentation at the 2024 AAAAI Annual Meeting highlighting preclinical data for AK006, demonstrating its ability to reduce MRGPRX2-induced skin inflammation by inhibiting mast cell activation.

Allakos Inc. announced the publication of new scientific results in Allergy, detailing how AK006 inhibits multiple modes of mast cell activation.

Allakos Inc. reports the retirement of its Chief Medical Officer, Dr. Craig Paterson, and the appointment of Dr. Chin Lee as his successor, effective February 9, 2024.

Allakos Inc. is halting development of lirentelimab, reducing its workforce by almost 50%, and focusing on its AK006 program, while also providing updates on recent clinical trial results.

Allakos Inc. is restructuring to focus on its AK006 program after Phase 2 trials for lirentelimab failed to meet primary endpoints, resulting in a 50% workforce reduction and a shift in strategic direction.